X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (17) 17
oncology (12) 12
humans (11) 11
melanoma (10) 10
female (8) 8
metastasis (8) 8
cancer (6) 6
animals (5) 5
article (5) 5
care and treatment (5) 5
chemotherapy (5) 5
health aspects (5) 5
prognosis (5) 5
research (5) 5
tumors (5) 5
breast cancer (4) 4
genetic aspects (4) 4
immunotherapy (4) 4
inhibition (4) 4
mutation (4) 4
phase-ii (4) 4
braf (3) 3
breast neoplasms - drug therapy (3) 3
breast neoplasms - metabolism (3) 3
cell line, tumor (3) 3
drug therapy (3) 3
efficacy (3) 3
epigenesis (3) 3
epigènesi (3) 3
growth (3) 3
kinases (3) 3
male (3) 3
medicine, research & experimental (3) 3
melanoma - drug therapy (3) 3
melanoma - pathology (3) 3
metastatic melanoma (3) 3
methylation (3) 3
metilació (3) 3
metàstasi (3) 3
mice (3) 3
neoplasms (3) 3
open-label (3) 3
proteïnes supressores de tumors (3) 3
review (3) 3
safety (3) 3
survival (3) 3
therapy (3) 3
trastuzumab (3) 3
treatment outcome (3) 3
tumor suppressor protein (3) 3
activation (2) 2
adult (2) 2
advanced melanoma (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
biotechnology & applied microbiology (2) 2
breast-cancer (2) 2
colon-cancer (2) 2
colorectal cancer (2) 2
dermatology (2) 2
development and progression (2) 2
gene mutations (2) 2
hek293 cells (2) 2
hematology, oncology and palliative medicine (2) 2
hepatitis (2) 2
inhibitors (2) 2
ipilimumab (2) 2
mek inhibitor (2) 2
melanoma - genetics (2) 2
middle aged (2) 2
neoplasms. tumors. oncology. including cancer and carcinogens (2) 2
nivolumab (2) 2
nras mutation (2) 2
patients (2) 2
protein kinase inhibitors - pharmacology (2) 2
proto-oncogene proteins b-raf - genetics (2) 2
proto-oncogene proteins b-raf - metabolism (2) 2
receptor (2) 2
receptor, erbb-2 - antagonists & inhibitors (2) 2
receptor, erbb-2 - metabolism (2) 2
receptors, estrogen - metabolism (2) 2
signal transduction (2) 2
signaling (2) 2
skin neoplasms - pathology (2) 2
usage (2) 2
vemurafenib - therapeutic use (2) 2
1st-line therapy (1) 1
1st-line treatment (1) 1
307 (1) 1
ablation (1) 1
acral (1) 1
acute kidney injury - chemically induced (1) 1
acute liver failure (1) 1
adaptor proteins, signal transducing - genetics (1) 1
adaptor proteins, signal transducing - metabolism (1) 1
adjuvant chemotherapy (1) 1
adrenal cortex hormones - administration & dosage (1) 1
adrenal cortex hormones - therapeutic use (1) 1
advanced (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Genetics, ISSN 1061-4036, 02/2015, Volume 47, Issue 3, pp. 250 - 256
Resistance to RAF-and MEK-targeted therapy is a major clinical challenge(1-4). RAF and MEK inhibitors are initially but only transiently effective in some but... 
COLON-CANCER | SURVIVAL | LUNG | ACTIVATION | INHIBITION | MELANOMA | SIGNALING PATHWAY | TRANSCRIPTION | GENETICS & HEREDITY | BRAF | KRAS | Humans | Molecular Targeted Therapy | Phosphoproteins - metabolism | Gene Knockdown Techniques | Heterografts | MAP Kinase Signaling System - genetics | HEK293 Cells | Female | MAP Kinase Kinase Kinases - antagonists & inhibitors | Protein-Serine-Threonine Kinases - metabolism | Proto-Oncogene Proteins B-raf - metabolism | MAP Kinase Kinase Kinases - genetics | Protein-Serine-Threonine Kinases - genetics | MAP Kinase Kinase Kinases - metabolism | Phosphoproteins - genetics | Mice, SCID | HT29 Cells | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Drug Resistance, Neoplasm - genetics | Animals | MAP Kinase Signaling System - drug effects | Proto-Oncogene Proteins B-raf - genetics | Adaptor Proteins, Signal Transducing - genetics | Cell Line, Tumor | Mice, Inbred NOD | Biomarkers, Tumor - genetics | Mice | Protein Kinase Inhibitors - pharmacology | Mutation | Adaptor Proteins, Signal Transducing - metabolism | Genes, ras | Antimitotic agents | Gene mutations | Genetic aspects | Research | Antineoplastic agents | Drug resistance | Health aspects | Thyroid cancer | Lung cancer | Colorectal cancer | Melanoma | Kinases | Charitable foundations | Cancer therapies | Design of experiments | Tumors
Journal Article
Nature, ISSN 0028-0836, 10/2018, Volume 562, Issue 7727, pp. 434 - 438
Basal cell carcinoma (BCC) is the most frequent cancer in humans and results from constitutive activation of the Hedgehog pathway(1). Several Smoothened... 
LINEAGE COMMITMENT | INITIATING CELLS | COLON-CANCER | STEM-CELLS | HEDGEHOG PATHWAY | MULTIDISCIPLINARY SCIENCES | EPIDERMIS | PROLIFERATION | DRUG-RESISTANCE | MOUSE SKIN | ADULT | Recurrence | Anilides - therapeutic use | Skin Neoplasms - drug therapy | Carcinoma, Basal Cell - genetics | Receptors, G-Protein-Coupled - metabolism | Humans | Hedgehog Proteins - metabolism | Male | Secondary Prevention | Wnt Proteins - metabolism | Cell Lineage - drug effects | Female | Smoothened Receptor - antagonists & inhibitors | Disease Models, Animal | Pyridines - therapeutic use | Skin Neoplasms - pathology | Pyridines - administration & dosage | Neoplasm Recurrence, Local - prevention & control | Carcinoma, Basal Cell - pathology | Hedgehog Proteins - antagonists & inhibitors | Withholding Treatment | Patched-1 Receptor - deficiency | Hair Follicle - drug effects | Hair Follicle - cytology | Animals | Wnt Signaling Pathway - drug effects | Anilides - administration & dosage | Cell Differentiation - drug effects | Skin Neoplasms - genetics | Anilides - pharmacology | Carcinoma, Basal Cell - drug therapy | Mice | Pyridines - pharmacology | Wnt Proteins - antagonists & inhibitors | Care and treatment | Usage | Basal cell carcinoma | Rats as laboratory animals | Genetic aspects | Vismodegib | Research | T cells | Cycles | Animal models | Wnt protein | Colorectal cancer | Regression | Shrinkage | Metastasis | Ablation | Mimicry | Signal transduction | Signaling | Inhibitors | Medulloblastoma | Cell cycle | Stem cells | Population | Genetic engineering | Mutation | Inhibition | Differentiation | Tumors
Journal Article
Nature Medicine, ISSN 1078-8956, 07/2015, Volume 21, Issue 7, pp. 741 - 750
Metastasis is responsible for most cancer-related deaths, and, among common tumor types, melanoma is one with great potential to metastasize. Here we study the... 
MEDICINE, RESEARCH & EXPERIMENTAL | INHIBITION | PROTEIN | BIOCHEMISTRY & MOLECULAR BIOLOGY | RESISTANCE | RECEPTOR | CANCER | CELL BIOLOGY | Transcriptional Activation - genetics | Immunoprecipitation | Molecular Weight | Prognosis | Transcriptional Activation - drug effects | GTPase-Activating Proteins - metabolism | RNA, Messenger - metabolism | Promoter Regions, Genetic - genetics | Neoplasm Metastasis | Receptor, Epidermal Growth Factor - metabolism | Protein Isoforms - metabolism | Melanoma - genetics | Protein Binding - drug effects | Epigenesis, Genetic - drug effects | rab GTP-Binding Proteins - metabolism | RNA, Messenger - genetics | Treatment Outcome | DNA Methylation - genetics | Melanoma - pathology | Disease Progression | Animals | Signal Transduction - drug effects | Mice, Nude | Cell Line, Tumor | Protein Kinase Inhibitors - pharmacology | GTPase-Activating Proteins - genetics | DNA Methylation - drug effects | Protein Isoforms - genetics | RNA, Small Interfering - metabolism | Studies | Metastasis | Deoxyribonucleic acid--DNA | Melanoma | Metilació | Epigènesi | Metàstasi | Proteïnes supressores de tumors | Epigenesis | Methylation | Tumor suppressor protein | Clinical Medicine | Basic Medicine | Medical Genetics | Medicinsk genetik | Medical and Health Sciences | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper | Cell and Molecular Biology | Cancer and Oncology | Klinisk medicin | Cell- och molekylärbiologi | Cancer och onkologi
Journal Article
Journal of Experimental Medicine, ISSN 0022-1007, 07/2018, Volume 215, Issue 7, pp. 1913 - 1928
Journal Article
Journal Article
European Journal of Cancer Supplements, ISSN 1359-6349, 2013, Volume 11, Issue 2, pp. 254 - 256
Journal Article
Current Breast Cancer Reports, ISSN 1943-4588, 6/2014, Volume 6, Issue 2, pp. 51 - 58
Recent advances in breast cancer research have allowed deconstruction of the molecular profile of the most relevant breast cancer subtypes. This has led to an... 
BGJ398 | FGFR amplification | Oncology | Internal Medicine | Breast cancer | Tyrosine kinase inhibitors | AZD4547 | Lucitanib (E-3810) | Medicine & Public Health | Dovitinib (TKI258) | Hyperphosphatemia | Surgical Oncology | Fibroblast growth factor receptor (FGFR) | Tyrosine kinase receptor | Care and treatment | Fibroblast growth factors | Drug therapy | Analysis | Cancer
Journal Article
SEMINARS IN ONCOLOGY, ISSN 0093-7754, 10/2014, Volume 41, Issue 5, pp. 576 - 588
The discovery of HER2 and development of trastuzumab pioneered the field of targeted therapy in breast cancer. Hoping to emulate the same clinical success,... 
INSULIN | MONOTHERAPY | INHIBITION | TRASTUZUMAB | MECHANISM | EFFICACY | ONCOLOGY | GROWTH | PHASE-II | RECEPTOR | CHEMOTHERAPY | Animals | Antigens, Neoplasm - immunology | Breast Neoplasms - immunology | Humans | Antibodies, Monoclonal - therapeutic use | Female | Breast Neoplasms - drug therapy | Antibodies, Monoclonal - immunology
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 10/2019, Volume 25, Issue 20, pp. 6061 - 6072
Purpose: Atezolizumab [anti-programmed death-ligand 1 (PD-L1)] selectively targets PD-L1 to block its interaction with receptors programmed death 1 and B7.1,... 
SURVIVAL | MULTICENTER | PEMBROLIZUMAB | ONCOLOGY | IMMUNOTHERAPY | PD-1 BLOCKADE | UROTHELIAL CARCINOMA | DEATH-LIGAND 1 | TUMOR RESPONSE | OPEN-LABEL | CHEMOTHERAPY
Journal Article
Journal Article